What is the recommended antimicrobial regimen and dosing for serious Pseudomonas aeruginosa infections?

Recommended Antimicrobial Regimen for Serious Pseudomonas aeruginosa Infections

For serious Pseudomonas aeruginosa infections, use ceftolozane-tazobactam (3 g IV q8h for pneumonia, 1.5 g IV q8h for other infections) or ceftazidime-avibactam (2.5 g IV q8h) as first-line therapy for difficult-to-treat resistant (DTR) strains; for carbapenem-resistant but otherwise susceptible strains, use standard antipseudomonal agents like piperacillin-tazobactam (3.375-4.5 g IV q6h), cefepime (2 g IV q8-12h), or ceftazidime (2 g IV q8h) as monotherapy. 1, 2, 3

Treatment Algorithm Based on Resistance Pattern

Step 1: Determine Resistance Phenotype

Carbapenem-Resistant but Susceptible to Other Agents (CRPA):

• Use susceptible antipseudomonal agents as monotherapy 1
• Options include:
  • Piperacillin-tazobactam 3.375-4.5 g IV q6h
  • Ceftazidime 2 g IV q8h
  • Cefepime 2 g IV q8-12h
  • Ciprofloxacin 400 mg IV q8h
  • Levofloxacin 750 mg IV daily
• Duration: 5-10 days for complicated UTI/intra-abdominal infections; 10-14 days for pneumonia/bloodstream infections 1

Difficult-to-Treat Resistance (DTR-PA): DTR-PA is defined as non-susceptibility to ALL of the following: ceftazidime, cefepime, piperacillin-tazobactam, aztreonam, carbapenems, and fluoroquinolones 2, 3

Step 2: First-Line Therapy for DTR-PA

Preferred agents (choose based on susceptibility):

1. Ceftolozane-tazobactam 1, 2, 4

   • For pneumonia (HAP/VAP): 3 g (2 g ceftolozane/1 g tazobactam) IV over 1 hour q8h
   • For other infections: 1.5 g IV q8h
   • Preferred for pneumonia over ceftazidime-avibactam 4

2. Ceftazidime-avibactam 1, 2, 4

   • 2.5 g IV q8h
   • Equally effective as ceftolozane-tazobactam for non-pulmonary infections 4

3. Imipenem-cilastatin-relebactam 1, 2, 4

   • 1.25 g IV q6h
   • Consider when resistance to ceftolozane-tazobactam or ceftazidime-avibactam exists (but no metallo-β-lactamases present)

Step 3: Alternative Agents for Specific Resistance Mechanisms

For Metallo-β-lactamase Producers:

• Cefiderocol is the preferred agent 4, 3
• Alternative: Aztreonam-avibactam (when available) 4
• Alternative: Ceftazidime-avibactam PLUS aztreonam combination 4

When Novel Agents Unavailable or Resistant:

• Colistin-based therapy 1
  • Loading dose: 5 mg CBA/kg IV
  • Maintenance: 2.5 mg CBA × (1.5 × CrCl + 30) IV q12h
  • Consider combination with carbapenem (if MIC ≤32 mg/L) for synergy 1
  • Colistin-carbapenem showed highest SUCRA ranking (83.6%) for clinical cure in network meta-analysis 1

Critical Management Considerations

Monotherapy vs. Combination Therapy

Monotherapy is preferred for DTR-PA when using novel β-lactams 2, 4, 5

• Combination therapy does NOT reduce mortality in clinical trials 4, 5
• Exception: Consider combination therapy on case-by-case basis for:
  • Severely immunocompromised patients
  • Empirical therapy pending susceptibilities
  • Consultation with infectious diseases specialist recommended 2

If combination therapy considered:

• Fosfomycin as companion agent may be reasonable 2
• Colistin plus carbapenem for colistin-susceptible strains 1

Dosing Optimization

Extended infusions for β-lactams:

• Carbapenems should be infused over >3 hours when used 1
• Maximizes time above MIC for concentration-dependent killing

Aminoglycosides:

• Amikacin 15 mg/kg IV daily (for susceptible strains) 1
• Monotherapy ONLY indicated for urinary tract infections 1
• Not recommended as monotherapy for serious infections 6

Common Pitfalls to Avoid

1. Do not use aminoglycoside monotherapy for serious infections outside the urinary tract - associated with treatment failure 1

2. Do not assume carbapenem resistance means resistance to all agents - many CRPA strains lose only OprD porin and remain susceptible to piperacillin-tazobactam, ceftazidime, or cefepime 2

3. Avoid colistin monotherapy when novel β-lactams are available and susceptible - colistin has narrow therapeutic window, high nephrotoxicity risk, and inferior outcomes 2, 4

4. Do not use tigecycline monotherapy for pneumonia - inadequate lung penetration 1

5. Resistance can emerge during therapy, particularly with imipenem - development of resistance occurred more frequently with imipenem versus comparators (RR 2.33) 6

Duration of Therapy

• Complicated UTI/intra-abdominal infections: 5-10 days 1
• Hospital-acquired/ventilator-associated pneumonia: 10-14 days 1
• Bloodstream infections: 10-14 days 1
• Individualize based on: infection site, source control, underlying comorbidities, and clinical response 1

Monitoring and Adjustment

For colistin therapy:

• Monitor renal function closely due to nephrotoxicity risk
• Adjust dosing based on creatinine clearance using formula provided 1

For all regimens:

• Reassess at 48-72 hours based on clinical response
• Consider infectious diseases consultation for complex cases 2, 3
• Verify susceptibility testing results and adjust therapy accordingly